View Older Stories View More Recent Stories

May 4, 2022 04:05PM Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million
May 2, 2022 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Apr 26, 2022 04:05PM Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022
Apr 1, 2022 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Mar 14, 2022 07:34AM Paratek Pharmaceuticals (PRTK) Reports FY 2021 Revenue of $130.2M
Mar 14, 2022 07:30AM Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million
Mar 8, 2022 04:06PM Paratek Pharmaceuticals (PRTK) Reports Publication of Data from an Investigator-Initiated Study of NUZYRA
Mar 8, 2022 04:05PM Paratek Pharmaceuticals Announces the Publication of Data from an Investigator-Initiated Study of NUZYRA® (omadacycline) in a Hollow Fiber System Model Against Pulmonary Mycobacterium avium complex
Mar 2, 2022 04:05PM Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022
Mar 1, 2022 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Feb 1, 2022 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jan 3, 2022 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dec 16, 2021 11:57AM Paratek Pharmaceuticals (PRTK) Partner Zai Lab (ZLAB) Gains China Approval for NUZYRA
Dec 16, 2021 11:36AM China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections 
Dec 1, 2021 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Nov 10, 2021 04:05PM Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
Nov 8, 2021 04:05PM Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021
Nov 1, 2021 04:05PM Paratek Pharmaceuticals to Report Third Quarter 2021 Financial Results on Nov. 8, 2021
Nov 1, 2021 04:04PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 18, 2021 04:05PM Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium absc
Oct 1, 2021 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sep 27, 2021 04:06PM Paratek Pharmaceuticals (PRTK) Announces Additional $19M BARDA Funding for Development of NUZYRA
Sep 27, 2021 04:05PM Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthr
Sep 23, 2021 04:05PM Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2021
Sep 9, 2021 08:30AM Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Sep 1, 2021 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Aug 18, 2021 04:13PM Paratek Pharmaceuticals (PRTK) Announces FDA Orphan Drug Designation for NUZYRA® (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria
Aug 18, 2021 04:12PM Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA® (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria
Aug 9, 2021 04:05PM Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021
Aug 4, 2021 04:36PM Paratek Pharmaceuticals (PRTK) Announces NUZYRA Has Been Added to the CDC Plague Guidelines for the Treatment, Pre-Exposure and Postexposure Prophylaxis of Plague
Aug 4, 2021 04:30PM Paratek Pharmaceuticals Announces NUZYRA® (omadacycline) Has Been Added to the CDC Plague Guidelines for the Treatment, Pre-Exposure and Postexposure Prophylaxis of Plague
Aug 3, 2021 04:30PM Paratek Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference 2021
Aug 2, 2021 04:35PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Aug 2, 2021 04:30PM Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021
Jun 29, 2021 08:04AM Paratek Pharmaceuticals (PRTK) Announces First BARDA Project BioShield Procurement of NUZYRA (omadacycline) Valued at ~$38 Million
Jun 29, 2021 08:00AM Paratek Pharmaceuticals Announces First BARDA Project BioShield Procurement of NUZYRA® (omadacycline) Valued at ~$38 Million
Jun 16, 2021 07:34AM Paratek Pharmaceuticals (PRTK) Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus Complex with NUZYRA
Jun 16, 2021 07:30AM Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline)
Jun 14, 2021 08:00AM Paratek Appoints Minnie Baylor-Henry to Company’s Board of Directors
Jun 10, 2021 08:00AM Paratek Pharmaceuticals Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on Non-Tuberculous Mycobacteria, M. abscessus
Jun 1, 2021 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jun 1, 2021 07:46AM Paratek Pharmaceuticals (PRTK) Announces FDA Approval of NUZYRA Oral Only Dosing Regimen for Treatment of CABP
Jun 1, 2021 07:45AM Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
May 26, 2021 04:17PM Paratek Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 17, 2021 07:30AM Paratek Pharmaceuticals Announces First Quarter 2021 Total Revenue of $16.4 Million and Initiation of First BARDA Procurement
May 10, 2021 04:05PM Paratek Pharmaceuticals to Report First Quarter 2021 Financial Results on May 17, 2021
May 3, 2021 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Apr 1, 2021 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Mar 1, 2021 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Feb 24, 2021 04:01PM Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of $46.9 Million including NUZYRA® (omadacycline) Net U.S. Sales of $38.8 Million
View More Recent Stories View Older Stories